- •Despite the available treatments, relief of symptoms of vulvovaginal atrophy in postmenopausal women remains unsatisfactory.
- •A better knowledge of the association between treatments, quality of life and symptoms may help disease management.
- •Postmenopausal women with vulvovaginal atrophy receiving treatment complained of higher number and more severe symptoms.
- •Women on systemic treatment had fewer and milder symptoms and presented with better vaginal and vulvar health.
- •The treatment of vulvovaginal atrophy should be initiated at early stages of the disease to prevent irreversible changes.
Main outcome measures
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Vulvovaginal atrophy–a tale of neglect.Climacteric. 2014; 17: 1-2https://doi.org/10.3109/13697137.2014.872519
- Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.Gynecol. Endocrinol. 2016; 32: 602-606https://doi.org/10.1080/09513590.2016.1183627
- Vulvovaginal atrophy.Mayo Clin. Proc. 2010; 85: 87-94https://doi.org/10.4065/mcp.2009.0413
- The REVIVE (Real Women’s Views of Treatment Options for Menopausal Vaginal Changes) survey in Europe: country-specific comparisons of postmenopausal women’s perceptions, experiences and needs.Maturitas. 2016; 91: 81-90https://doi.org/10.1016/j.maturitas.2016.06.010
- Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.J. Sex. Med. 2013; 10: 1790-1799https://doi.org/10.1111/jsm.12190
- Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.Climacteric. 2014; 17: 3-9https://doi.org/10.3109/13697137.2013.871696
- The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe.J. Womens Health (Larchmt). 2015; https://doi.org/10.1089/jwh.2014.5177
- Recommendations for the management of postmenopausal vaginal atrophy.Climacteric. 2010; 13: 509-522https://doi.org/10.3109/13697137.2010.522875
- The 2012 hormone therapy position statement of: The North American Menopause Society.Menopause. 2012; 19: 257-271https://doi.org/10.1097/gme.0b013e31824b970a
- Treatment of the genitourinary syndrome of menopause.Climacteric. 2015; 18: 23-29https://doi.org/10.3109/13697137.2015.1079100
- Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.Clin. Interv. Aging. 2014; 9: 1939-1950https://doi.org/10.2147/CIA.S73753
- Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.Pharmacotherapy. 2014; 34: 1050-1060https://doi.org/10.1002/phar.1465
- Ospemifene: a novel option for the treatment of vulvovaginal atrophy.J. Menopausal Med. 2017; 23: 79https://doi.org/10.6118/jmm.2017.23.2.79
- Members of the VVA prasterone research group, effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy.J. Sex. Med. 2015; 12: 2401-2412https://doi.org/10.1111/jsm.13045
- Vaginal rejuvenation using energy-based devices.Int. J. Womens Dermatol. 2016; 2: 85-88https://doi.org/10.1016/j.ijwd.2016.05.003
- The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.Climacteric. 2018; 21: 286-291https://doi.org/10.1080/13697137.2018.1446930
- Medical and patient attitude towards vaginal atrophy: the AGATA study.Climacteric. 2016; 19: 553-557https://doi.org/10.1080/13697137.2016.1240770
- Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: the AGATA study.Maturitas. 2016; 83: 40-44https://doi.org/10.1016/j.maturitas.2015.09.001
- EuroQol--a new facility for the measurement of health-related quality of life.Health Policy. 1990; 16: 199-208
- Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women.Menopause. 2015; 22: 144-154https://doi.org/10.1097/GME.0000000000000281
- The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores.J. Sex Marital Ther. 2005; 31: 1-20https://doi.org/10.1080/00926230590475206
- Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder.J. Sex. Med. 2008; 5: 357-364https://doi.org/10.1111/j.1743-6109.2007.00672.x
- Urogenital ageing: an old problem newly recognized.Maturitas. 1995; : S1-S5
- Vaginal atrophy in the postmenopausal woman: the importance of sexual activity and hormones.JAMA. 1983; 249: 2195-2198https://doi.org/10.1001/jama.1983.03330400041022
- Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.Climacteric. 2016; 19: 188https://doi.org/10.3109/13697137.2015.1107039
- As the writing group of the GENISSE study, Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.Climacteric. 2018; 21: 167-173https://doi.org/10.1080/13697137.2017.1421921
- Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.Menopause. 2012; 19: 109-117https://doi.org/10.1097/gme.0b013e31821f92df
- A prospective population-based study of menopausal symptoms.Obstet. Gynecol. 2000; 96: 351-358
- Efficacy and tolerability of local estrogen therapy for urogenital atrophy.Menopause. 2010; 17: 194-203https://doi.org/10.1097/gme.0b013e3181a95581
- Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study.Climacteric. 2014; 17: 29-36https://doi.org/10.3109/13697137.2013.850480
- British Menopause Society medical advisory council, BMS – consensus statement.Post Reprod. Health. 2018; 24: 133-138https://doi.org/10.1177/2053369118795349